BUZZ-Vir Biotechnology soars on Q4 results beat, Astellas collaboration

Reuters

Feb 24

BUZZ-<a href="https://laohu8.com/S/VIR">Vir Biotechnology</a> soars on Q4 results beat, Astellas collaboration

** Shares of drug developer Vir Biotechnology VIR.O rise 65.2% at $12.28 premarket

** Co posts Q4 revenue of $64.1 mln, beating analyst est. of $23.1 mln; posts Q4 loss per share of 31 cents, compared with the consensus of loss of 49 cents - data compiled by LSEG

** Co highlights its agreement with Norgine and lower R&D expenses due to restructuring initiatives

** Co also plans to develop and commercialize its prostate cancer experimental drug with Japan's Astellas 4503.T

** As of last close, VIR stock up 23.2% YTD, following a 17.8% decline in 2025

(Reporting by Tharuniyaa Lakshmi in Bengaluru)

((tharuniyaa@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2613797955"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613797955\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613797955?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 18:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613797955","market":"fut","top_or_hot":-1,"title":"BUZZ-Vir Biotechnology soars on Q4 results beat, Astellas collaboration","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> soars on Q4 results beat, Astellas collaboration</title></head><body><p>** Shares of drug developer Vir Biotechnology <span>VIR.O</span> rise 65.2% at $12.28 premarket </p><p>** Co <span>posts Q4</span> revenue of $64.1 mln, beating analyst est. of $23.1 mln; posts Q4 loss per share of 31 cents, compared with the consensus of loss of 49 cents - data compiled by LSEG</p><p>** Co highlights its agreement with Norgine and lower R&amp;D expenses due to restructuring initiatives </p><p>** Co also plans to develop and commercialize its prostate cancer experimental drug <span>with Japan's</span> Astellas <span>4503.T</span></p><p>** As of last close, VIR stock up 23.2% YTD, following a 17.8% decline in 2025</p><p> (Reporting by Tharuniyaa Lakshmi in Bengaluru)</p><p> ((tharuniyaa@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Vir Biotechnology soars on Q4 results beat, Astellas collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Vir Biotechnology soars on Q4 results beat, Astellas collaboration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-24 18:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> soars on Q4 results beat, Astellas collaboration</title></head><body><p>** Shares of drug developer Vir Biotechnology <span>VIR.O</span> rise 65.2% at $12.28 premarket </p><p>** Co <span>posts Q4</span> revenue of $64.1 mln, beating analyst est. of $23.1 mln; posts Q4 loss per share of 31 cents, compared with the consensus of loss of 49 cents - data compiled by LSEG</p><p>** Co highlights its agreement with Norgine and lower R&amp;D expenses due to restructuring initiatives </p><p>** Co also plans to develop and commercialize its prostate cancer experimental drug <span>with Japan's</span> Astellas <span>4503.T</span></p><p>** As of last close, VIR stock up 23.2% YTD, following a 17.8% decline in 2025</p><p> (Reporting by Tharuniyaa Lakshmi in Bengaluru)</p><p> ((tharuniyaa@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL6N3ZK0NW:1","article_id":"2613797955","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613797955","pubTimestamp":1771929721,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Vir Biotechnology soars on Q4 results beat, Astellas collaboration** Shares of drug developer Vir Biotechnology VIR.O rise 65.2% at $12.28 premarket ** Co posts Q4 revenue of $64.1 mln, beating analyst est. of $23.1 mln; posts Q4 loss per share of 31 cents, compared with the consensus of loss of 49 cents - data compiled by LSEG** Co highlights its agreement with Norgine and lower R&D expenses due to restructuring initiatives ** Co also plans to develop and commercialize its prostate cancer experimental drug with Japan's Astellas 4503.T** As of last close, VIR stock up 23.2% YTD, following a 17.8% decline in 2025  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓","BK4139":"生物科技","VIR":"Vir Biotechnology, Inc."},"translate_title":"BUZZ-Vir Biotechnology因第四季度业绩好于安斯泰来合作而飙升","themeId":"820bd9599ffb63504ba3f82e9df01528","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":0.9},"content_text":"BUZZ-Vir Biotechnology soars on Q4 results beat, Astellas collaboration** Shares of drug developer Vir Biotechnology VIR.O rise 65.2% at $12.28 premarket ** Co posts Q4 revenue of $64.1 mln, beating analyst est. of $23.1 mln; posts Q4 loss per share of 31 cents, compared with the consensus of loss of 49 cents - data compiled by LSEG** Co highlights its agreement with Norgine and lower R&D expenses due to restructuring initiatives ** Co also plans to develop and commercialize its prostate cancer experimental drug with Japan's Astellas 4503.T** As of last close, VIR stock up 23.2% YTD, following a 17.8% decline in 2025 (Reporting by Tharuniyaa Lakshmi in Bengaluru) ((tharuniyaa@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}